View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Suvoda WP
September 5, 2017updated 11 Jul 2022 9:56am

UK NICE issues second draft ‘no’ on Ninlaro to treat myeloma patients

The UK National Institute for Health and Care Excellence (NICE) has issued a second draft ‘no’ on Takeda’s Ninlaro (ixazomib) for the treatment of patients with relapsed or refractory myeloma.

By Lopamudra Roy

The UK National Institute for Health and Care Excellence (NICE) has issued a second draft ‘no’ on Takeda’s Ninlaro (ixazomib) for the treatment of patients with relapsed or refractory myeloma.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Also known as multiple myeloma, relapsed or refractory myeloma is a cancer caused by abnormal cells in the bone marrow.

Ixazomib is an oral medication and a proteasome inhibitor used to treat multiple myeloma in combination with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior treatment for their disease.

Myeloma UK acting policy and public affairs manager Shelagh McKinlay said: “This second draft ‘no’ is disappointing, but while the consultation is ongoing there is still the potential for a positive decision to be reached.

“We are glad that NICE have decided to seek further views before reaching a final decision.”

"Triple combination treatments such as this one are becoming the international standard in myeloma treatment and patients in the UK deserve to have access to them."

Though the final decision on the use of the treatment has not yet been taken, NICE does not currently intend to recommend the myeloma therapy to be made routinely available for patients on the National Health Service (NHS) in England and Wales.

The decision was taken for the treatment combination of ixazomib, lenalidomide and dexamethasone, and will not affect patients who are already being treated with ixazomib, either through the Named Patient Programme (NPP) or on a clinical trial.

McKinlay added: “Triple combination treatments such as this one are becoming the international standard in myeloma treatment and patients in the UK deserve to have access to them.

“Ixazomib is not only an effective treatment option, it is the first oral treatment of its kind, offering patients much needed flexibility in how they live their lives.

“The company has requested that the treatment be considered for funding through the new Cancer Drugs Fund (CDF).”

Myeloma UK is the only organisation in the country that focuses entirely on the treatment options of myeloma.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology